CareLit Fachartikel
Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment
P Buggisch, J Petersen, K Wursthorn, A Gauthier, P Atanasov · Zeitschrift für Gastroenterologie · 2015 · Heft 08
Dokument
1145495
CareLit-ID
Jahr
2015
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Background and Aims: Ledipasvir/Sofosbuvir (LDV/SOF) single tablet regimen (STR) is approved in Europe for chronic hepatitis C (CHC) patients with genotypes (GT) 1, 3 and 4. In the ION-3 study 8 weeks (8w) of LDV/SOF was non-inferior to 12 w in previously untreated GT1 patients without cirrhosis with no benefit for the addition of Ribavirin. According to the SPC 8w may be considered in this population. The aim of the present analysis is to characterise the population receiving 8w LDV/SOF and to describe outcomes in clinical practice. Methods: The first CHC patients treated with 8w LDV/SOF in a single centre in G…
Schlagworte
Population
Hepatitis
Depression
Germany
After
Zeitschrift für Gastroenterologie
